Clinical Instructor, Medicine, Tufts Medical Center
Emergency Medicine
Dr. David J. Petillo, MD
|
|
Give Review
David Petillo works in the field of Emergency Medicine. He graduated from Georgetown University School of Medicine. Georgetown University School of Medicine has a rank of 49 in research and a 84 in primary care David Petillo is a published doctor. He has 31 papers published. The most current publication "Disruption of tubular Flcn expression as a mouse model for renal tumor induction." He is registered with Medicare.
Publications
- Disruption of tubular Flcn expression as a mouse model for renal tumor induction.
- Over-expression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells.
- CUL3 and NRF2 Mutations Confer an NRF2 Activation Phenotype in a Sporadic Form of Papillary Renal Cell Carcinoma.
- An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.
- Host response transcriptional profiling reveals extracellular components and ABC (ATP-binding cassette) transporters gene enrichment in typhoid fever-infected Nigerian...
- Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
- Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma.
- Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis.
- Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression.
- Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
- Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.
- Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.
- p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion.
- MicroRNA profiling of human kidney cancer subtypes.
- Genome-wide scan identifies novel modifier loci of acromegalic phenotypes for isolated familial somatotropinoma.
- Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.
- A comparison study reveals important features of agreement and disagreement between summarized DNA and RNA data obtained from renal cell carcinoma.
- Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated [corrected] oxygen-sensing response.
- Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC.
- Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma.
- The E2F3-Oncomir-1 axis is activated in Wilms' tumor.
- Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature.
- Detection of submicroscopic constitutional chromosome aberrations in clinical diagnostics: a validation of the practical performance of different array platforms.
- Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells.
- Human gene mutations. Gene symbol: HRPT2. Disease: Hyperparathyroidism Jaw-tumor syndrome.
- Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP).
- The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas.
- HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours.
- Inactivation of BHD in sporadic renal tumors.
- HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome.
Schools
Georgetown University
Worcester Memorial Hospital
Worcester Meml Hospital
Doctors Specialties
- Internal Medicine
- Emergency Medicine
Accepted Insurances
- Blue Cross Blue Shield
- Great West Healthcare-Cigna PPO
- LocalPlus
- Commercial Insurance Company
- Fallon Community Health Plan
- GEHA
- Harvard Pilgrim Health Care PPO
- Humana
- Medicare MCR
- Tricare
- United Healthcare
Education
-
Georgetown University School of Medicine
Hospital
-
Signature Healthcare Brockton Hospital
Drug Facts
| NPI NUMBER | 1285669614 | |
| NPPES Provider LastName | PETILLO | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 023023308 | |
| NPPES Provider State | MA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 226.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 54.0 | |
| Percent Opioid Claims | 23.89 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285669614 |
| Last Name Of The Provider | PETILLO |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Bonnie J. Ryan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jon S. Jancaterino, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald P. Jackel, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul L. Willis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jon A. Hojnoski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Glenn W. Allison, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark L. Haberman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ashraf F. Elkerm, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jan C. Rockwood, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Imran Karim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anthony G. Drappi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sham R. Khalsa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark T. Collins, MD
This Doctor is OpenDoctor Recommended.
|